米吉珠单抗改善中重度活动性克罗恩病患者生活质量与工作效率:3期VIVID-1研究结果
VIVID-1研究纳入米吉珠单抗组579例和安慰剂组199例中重度活动性克罗恩病患者,评估健康相关生活质量与工作效率。第12周和第52周,米吉珠单抗较安慰剂在IBDQ、SF-36、EQ-5D-5L视觉模拟量表及工作效率与活动受损问卷多项指标上均显著改善,且疗效维持至第52周。
要点
- 米吉珠单抗组较安慰剂组在IBDQ总分及各领域评分、SF-36汇总及领域评分、EQ-5D-5L视觉模拟量表评分的均值变化均显著改善(均P<0.001)。
- 第12周工作效率与活动受损问卷-克罗恩病各项评分显著改善:缺勤(P=0.001)、出勤主义(P=0.005)、活动受损(P<0.001)、整体工作受损(P=0.002)。
- 第52周上述工作效率改善维持(除缺勤外均P<0.001),且IBDQ应答、IBDQ缓解及SF-36生理与心理汇总成分临床重要改善的患者比例均高于安慰剂组(均P<0.001)。
核心结论
- 中重度活动性克罗恩病患者接受米吉珠单抗治疗,第12周健康相关生活质量和工作效率较安慰剂组有临床意义的改善,并维持至第52周。
研究设计与样本
- 3期VIVID-1研究,患者随机接受米吉珠单抗(N=579)或安慰剂(N=199),于第12周和第52周评估健康相关生活质量与工作效率。
主要发现
- 从基线至第12周和第52周,米吉珠单抗组较安慰剂组在IBDQ总分及各领域评分、SF-36汇总及领域评分、EQ-5D-5L视觉模拟量表评分的均值变化更大(均P<0.001)。
- 第12周工作效率与活动受损问卷-克罗恩病评分:缺勤(P=0.001)、出勤主义(P=0.005)、活动受损(P<0.001)、整体工作受损(P=0.002),米吉珠单抗组较安慰剂组显著改善。
- 第52周上述工作效率改善维持(除缺勤外均P<0.001)。
- 第12周和第52周,米吉珠单抗组较安慰剂组达到IBDQ应答、IBDQ缓解及SF-36生理与心理汇总成分临床重要改善的患者比例更高(均P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Mirikizumab demonstrated significant efficacy compared with placebo in patients with Crohn's disease (CD) in the phase 3 VIVID-1 study. In this study, we report the impact of mirikizumab vs placebo on health-related quality of life (HRQoL) and work productivity in VIVID-1. METHODS: VIVID-1 patients randomized to receive mirikizumab (N = 579), or placebo (N = 199) were included. The effect of mirikizumab on HRQoL was assessed at weeks 12 and 52 using the Inflammatory Bowel Disease Questionnaire (IBDQ), Short Form-36 Health Survey (SF-36), EQ-5D-5L visual analog scale, and Work Productivity and Activity Impairment: CD measures. The Cochran-Mantel-Haenszel test with nonresponder imputation (binary end points) and analysis of covariance with modified baseline observation carried forward (continuous end points) were used for treatment comparisons. RESULTS: Greater improvements in the mean change from baseline to weeks 12 and 52 were observed with mirikizumab vs placebo in IBDQ total and domain scores, SF-36 summary and domain scores, and EQ-5D-5L visual analog scale scores (all P < 0.001). Significant improvements with mirikizumab vs placebo were observed in Work Productivity and Activity Impairment:CD scores at week 12: absenteeism ( P = 0.001), presenteeism ( P = 0.005), activity impairment ( P < 0.001), and overall work impairment ( P = 0.002); these improvements were maintained at week 52 (all P < 0.001, except absenteeism). At weeks 12 and 52, a greater proportion of mirikizumab-treated patients vs placebo achieved IBDQ response, IBDQ remission, and clinically important improvement in physical and mental component summaries of SF-36 (all P < 0.001). DISCUSSION: Patients with moderately to severely active CD treated with mirikizumab reported clinically meaningful improvements in HRQoL and work productivity vs placebo at week 12, which were maintained at week 52.
引用
- Lee SD, Vermeire S, Ungaro R, et al. Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study. Am J Gastroenterol. 2025. PMID: 40079470. doi:10.14309/ajg.0000000000003410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。